摘要
目的探究应用诺和锐特充与诺和灵R治疗妊娠期糖尿病患者的临床疗效与安全性。方法选取本院2017年8月至2018年8月收治的76例妊娠期糖尿病患者,采取随机数字法分为研究组及参照组,每组38例。参照组给予诺和灵R控制血糖,研究组给予诺和锐特充控制血糖,比较两组疗效及安全性。结果研究组治疗总有效率高于参照组(P<0.05);用药前,两组血糖水平比较差异无统计学意义;分娩前,两组血糖均得到控制,但研究组FBG、2 h FBG以及HbA1c血糖水平低于参照组(P<0.05);研究组羊水过多、早产、新生儿呼吸窘迫等总发生率均低于参照组(P<0.05);研究组不良反应发生率均低于参照组(P<0.05)。结论诺和锐特充治疗妊娠期糖尿病的效果优于诺和灵R,且可在降低血糖的同时改善母婴围生期结局,提高用药的安全性,具有临床推广价值。
Objective To explore the clinical efficacy and safety of Novo Retech and Novo Ling R in the treatment of gestational diabetes.Methods 76 gestational diabetes patients admitted to our hospital from August 2017 to August 2018 were selected and divided into study group and reference group by random number method,with 38 cases in each group.The reference group was given Novo Ling R to control blood glucose,and the study group was given Novo Retech to control blood glucose,comparing the efficacy and safety of the two groups.Results The total effective rate of treatment in the study group was higher than that in the reference group(P<0.05).Before medication,there was no significant difference in blood glucose between the two groups.Before delivery,the blood glucose in both groups were controlled,but the FBG,2 h FBG and HbA1c in the study group was lower than that of the reference group(P<0.05).The incidence of polyhydramnios,premature delivery,and neonatal respiratory distress in the study group were lower than that of the reference group(P<0.05).The incidence of adverse reactions in the study group was lower than that of the reference group(P<0.05).Conclusion Nuohe Ruite is better than Novo ling R in the treatment of gestational diabetes,and it can improve the perinatal outcomes of mothers and infants while lowering blood glucose,and improve the safety of medication.
作者
杜侠
Du Xia(Linyi Traditional Chinese Medicine Hospital of Shandong Province,Linyi,Shandong,276000,China)
出处
《当代医学》
2020年第27期18-20,共3页
Contemporary Medicine
